RT Journal Article
SR Electronic
T1 Antibody Responses after SARS-CoV-2 Vaccination in Lymphoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.05.21258311
DO 10.1101/2021.06.05.21258311
A1 Sean Hua Lim
A1 Nicola Campbell
A1 Marina Johnson
A1 Debora Joseph-Pietras
A1 Graham P Collins
A1 Ann O’Callaghan
A1 Christopher P Fox
A1 Matthew Ahearne
A1 Peter WM Johnson
A1 David Goldblatt
A1 Andrew J Davies
YR 2021
UL http://medrxiv.org/content/early/2021/06/12/2021.06.05.21258311.abstract
AB Individuals with lymphoid malignancies have an increased mortality risk from COVID-19. Paradoxically, this population is least likely to be protected by SARS-CoV-2 vaccination as a result of disease- or treatment-related immunosuppression. Current data on vaccine responses in persons with lymphoid malignancies is limited.PROSECO is a UK multi-centre prospective observational study evaluating COVID-19 vaccine immune responses in individuals with lymphoma. This early interim analysis details the antibody responses to first- and second-SARS-CoV-2 vaccination with either BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca), in 129 participants. Responses are compared to those obtained in healthy volunteers.The key findings of this interim analysis are first, 61% of participants who are vaccinated during or within 6 months of receiving systemic anti-lymphoma treatment, do not have detectable antibodies despite two doses of vaccine. Second, individuals with curable disease such has Hodgkin (6/6) and aggressive B-cell non-Hodgkin lymphoma (13/16) develop robust antibody levels to either first or second doses, when vaccinated > 6 months after treatment completion. Third, participants incurable, indolent lymphomas have reduced antibody levels to first and second vaccine doses, irrespective of treatment history. Finally, whilst there was no difference in antibody responses between BNT162b2 and ChAdOx1 in lymphoma participants, BNT162b2 induces 11-fold higher antibody responses than ChAdOx1 after the second dose in healthy donors.These findings serve to reassure the community that individuals with treated Hodgkin and aggressive B-NHL can develop antibody responses to SARS-CoV-2 vaccine. Simultaneously it also highlights the critical need to identify an alternative strategy against COVID-19 for those undergoing systemic anti-lymphoma treatment, and for individuals with indolent lymphomas.Competing Interest StatementSHL, NC, MJ, DJP, AO, PWMJ and DG declare no competing interests. CF receives consultancy fees from AstraZeneca and participates in an advisory board for AstraZeneca, MA receives research funding from Pfizer, GPC receives research funding from Pfizer and participates in advisory boards for AstraZeneca and Pfizer, and AJD reports receiving research funding and honoraria from AstraZeneca and Janssen. Clinical TrialNCT04858568Funding StatementThe PROSECO study is funded by The Vaccine Blood Cancer Research Funding Consortium, and all charity partners including Blood Cancer UK (21009), and supported by Cancer Research UK Advanced Clinician Scientist Fellowship to SHL (A27179), Cancer Research UK/NIHR Southampton Experimental Cancer Medicine Centre funding and the NIHR Clinical Research Facility Southampton Research Biorepository (SRB). DG receives support from the NIHR Great Ormond Street Biomedical Research Centre. No pharmaceutical company contributed to this study or the writing of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work is approved by local research ethics committees and the UK NHS Health Research Authority (IRAS 294739; 233768). Healthy controls were vaccinees who received vaccine as part of the government rollout and donated serum post vaccination for essay evaluation. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data from this study is available after study completion on request to the corresponding author.